COVID-19 infection and vaccination in immunodeficiency

During the last 2 years and a half, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, causing about 6 million deaths. Clinical manifestations are highly variable, ranging from entirely asymptomatic infection to multiorgan failure and death. The outcome in immunocompr...

Descripción completa

Detalles Bibliográficos
Autores principales: Piano Mortari, Eva, Pulvirenti, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Editors’ Choice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384801/
https://www.ncbi.nlm.nih.gov/pubmed/35972956
http://dx.doi.org/10.1093/cei/uxac080
_version_ 1784769467568357376
author Piano Mortari, Eva
Pulvirenti, Federica
author_facet Piano Mortari, Eva
Pulvirenti, Federica
author_sort Piano Mortari, Eva
collection PubMed
description During the last 2 years and a half, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, causing about 6 million deaths. Clinical manifestations are highly variable, ranging from entirely asymptomatic infection to multiorgan failure and death. The outcome in immunocompromised patients is still a matter of debate, and so are the optimal strategies to prevent or treat the infection in these high-risk populations.
format Online
Article
Text
id pubmed-9384801
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-93848012022-08-18 COVID-19 infection and vaccination in immunodeficiency Piano Mortari, Eva Pulvirenti, Federica Clin Exp Immunol Editors’ Choice During the last 2 years and a half, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, causing about 6 million deaths. Clinical manifestations are highly variable, ranging from entirely asymptomatic infection to multiorgan failure and death. The outcome in immunocompromised patients is still a matter of debate, and so are the optimal strategies to prevent or treat the infection in these high-risk populations. Oxford University Press 2022-08-16 /pmc/articles/PMC9384801/ /pubmed/35972956 http://dx.doi.org/10.1093/cei/uxac080 Text en © Crown copyright 2022. This article contains public sector information licensed under the Open Government Licence v3.0 (https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
spellingShingle Editors’ Choice
Piano Mortari, Eva
Pulvirenti, Federica
COVID-19 infection and vaccination in immunodeficiency
title COVID-19 infection and vaccination in immunodeficiency
title_full COVID-19 infection and vaccination in immunodeficiency
title_fullStr COVID-19 infection and vaccination in immunodeficiency
title_full_unstemmed COVID-19 infection and vaccination in immunodeficiency
title_short COVID-19 infection and vaccination in immunodeficiency
title_sort covid-19 infection and vaccination in immunodeficiency
topic Editors’ Choice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384801/
https://www.ncbi.nlm.nih.gov/pubmed/35972956
http://dx.doi.org/10.1093/cei/uxac080
work_keys_str_mv AT pianomortarieva covid19infectionandvaccinationinimmunodeficiency
AT pulvirentifederica covid19infectionandvaccinationinimmunodeficiency

Ejemplares similares